Page last updated: 2024-10-19

niacinamide and Necrosis

niacinamide has been researched along with Necrosis in 62 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.

Research Excerpts

ExcerptRelevanceReference
"In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4',6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging)."7.85Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. ( Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B, 2017)
"Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC), the most frequent form of primary liver tumour."7.81The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. ( Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z, 2015)
"Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC)."7.81Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib. ( Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC, 2015)
"The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines."7.80Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014)
"To retrospectively compare radiofrequency ablation (RFA) combined with the multikinase inhibitor sorafenib (hereafter, sorafenib-RFA) and RFA alone in the treatment of hepatocellular carcinoma (HCC)."7.80Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis. ( Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K, 2014)
"The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines."7.79Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. ( Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E, 2013)
"To investigate the effects of sorafenib when combined with radiofrequency ablation treatment in liver tissue, the necrosis volume, tissue repair and hepatocellular growth signals were analyzed in rats."7.78Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. ( Bruners, P; Frei, P; Geier, A; Herweg, C; Mahnken, AH; Martin, IV; Mertens, JC; Müllhaupt, B; Schmitt, J, 2012)
"Twenty-five patients with inoperable hepatocellular carcinoma receiving oral sorafenib underwent magnetic resonance imaging at baseline and follow-up every 8 weeks (range, 2-19 weeks; mean, 7."7.77Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. ( Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D, 2011)
" We previously showed that the multikinase inhibitor sorafenib activated GSK-3β and that this activation attenuated the cytotoxic effects of the drug in various BRAF-mutant melanoma cell lines."7.77Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. ( Liu, Q; Mier, JW; Panka, DJ, 2011)
"As sorafenib induces early intralesional necrosis with profound changes in T1WI/T2WI MRI signal intensities and measurable necrotic tumor areas in most HCC patients, early MRI-based evaluation could pave the way for its rationale and cost-effective application."7.75Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. ( Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C, 2009)
"Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer."5.17Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. ( Agrawal, S; Choudhury, A; Denley, H; Eustace, A; Harris, AL; Hoskin, PJ; Irlam, JJ; Ord, JJ; Rojas, AM; Ryder, D; Taylor, J; West, CM, 2013)
"In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4',6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging)."3.85Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. ( Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B, 2017)
"To investigate feasibility, safety, and effect of transarterial chemoembolization using sorafenib on degree of tumor necrosis in a rabbit VX2 liver tumor model."3.83Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect. ( Kim, do Y; Kim, GM; Kim, MD; Kim, SH; Lee, do Y; Park, SI; Shin, M; Shin, W; Won, JY, 2016)
" Ex vivo treatment with 20 µM sorafenib induced apoptosis in around 80 % myeloma cells from six multiple myeloma patients."3.81Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. ( Anel, A; Azaceta, G; Galán-Malo, P; Jarauta, V; López-Royuela, N; Marzo, I; Naval, J; Palomera, L; Pardo, J; Ramírez-Labrada, A, 2015)
"Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC), the most frequent form of primary liver tumour."3.81The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. ( Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z, 2015)
"Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC)."3.81Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib. ( Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC, 2015)
"The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines."3.80Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014)
"To retrospectively compare radiofrequency ablation (RFA) combined with the multikinase inhibitor sorafenib (hereafter, sorafenib-RFA) and RFA alone in the treatment of hepatocellular carcinoma (HCC)."3.80Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis. ( Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K, 2014)
"Ferroptosis is a recently identified form of regulated necrosis that can be experimentally induced in cancer cells with the chemical inducer erastin."3.80Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. ( Baert, M; Chauffert, B; Diouf, M; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Saidak, Z, 2014)
"The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines."3.79Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. ( Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E, 2013)
"To investigate the effects of sorafenib when combined with radiofrequency ablation treatment in liver tissue, the necrosis volume, tissue repair and hepatocellular growth signals were analyzed in rats."3.78Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. ( Bruners, P; Frei, P; Geier, A; Herweg, C; Mahnken, AH; Martin, IV; Mertens, JC; Müllhaupt, B; Schmitt, J, 2012)
"Twenty-five patients with inoperable hepatocellular carcinoma receiving oral sorafenib underwent magnetic resonance imaging at baseline and follow-up every 8 weeks (range, 2-19 weeks; mean, 7."3.77Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. ( Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D, 2011)
" We previously showed that the multikinase inhibitor sorafenib activated GSK-3β and that this activation attenuated the cytotoxic effects of the drug in various BRAF-mutant melanoma cell lines."3.77Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. ( Liu, Q; Mier, JW; Panka, DJ, 2011)
"As sorafenib induces early intralesional necrosis with profound changes in T1WI/T2WI MRI signal intensities and measurable necrotic tumor areas in most HCC patients, early MRI-based evaluation could pave the way for its rationale and cost-effective application."3.75Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. ( Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C, 2009)
" administration of D-galactosamine, and it rather showed a decrease together with necrosis after carbon tetrachloride administration."3.68N1-methylnicotinamide level in the blood after nicotinamide loading as further evidence for malignant tumor burden. ( Fujimura, S; Kato, N; Miyazaki, M; Moriyama, Y; Nakagawa, K; Okui, K, 1991)
"Many muscle-invasive bladder cancers are hypoxic, which limits the efficacy of radiation therapy."3.01Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). ( Choudhury, A; Hoskin, PJ; Irlam, J; Lane, B; Mistry, H; Song, YP; Valentine, H; West, C; Yang, L, 2021)
"The osteosarcoma was only partially sensitive to the molecular-targeting drug sorafenib, which did not arrest its growth."1.46Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. ( Chishima, T; Dry, SM; Eilber, FC; Elliott, I; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Nelson, SD; Russell, T; Singh, A; Tanaka, K; Yanagawa, J; Zhang, Y; Zhao, M, 2017)
"Insufficient thermal ablation promotes residual tumor progression."1.43Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model. ( Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL, 2016)
"Relapsed/refractory Hodgkin's lymphoma (HL) is an unmet medical need requiring new therapeutic options."1.40BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. ( Anichini, A; Carbone, A; Carlo-Stella, C; Cleris, L; Locatelli, SL; Malorni, W; Pierdominici, M; Saba, E; Stirparo, GG; Tartari, S, 2014)
"Sorafenib was acutely administered to NASH rats with IR liver injury that were or were not chronically pretreated with the Rho-kinase-specific inhibitor fasudil."1.38Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. ( Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC, 2012)
"Spontaneous pyopneumothorax is a very rare occurrence, even in cancer treated patients."1.36Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases. ( Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S, 2010)
"Necrosis was also induced by DEVD-fmk, but not by YVAD-cmk, indicating that only inhibitors of caspase-3 were able to cause necrosis."1.32Inhibition of caspase-mediated PARP-1 cleavage results in increased necrosis in isolated islets of Langerhans. ( Aikin, R; Maysinger, D; Paraskevas, S; Rosenberg, L, 2004)
" However, the dosage and time of treatment require clarification."1.31Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model. ( Adams, JD; Chan, P; Chang, ML; Kem, S; Klaidman, LK; Sugawara, T; Yang, J, 2002)
" Furthermore, chronic administration of 0."1.27Enhancement of DEN initiation of liver carcinogenesis by inhibitors of NAD+ ADP ribosyl transferase in rats. ( Denda, A; Emi, Y; Konishi, Y; Mikami, S; Nakae, D; Ohnishi, T; Takahashi, S; Yokose, Y, 1984)

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-199016 (25.81)18.7374
1990's7 (11.29)18.2507
2000's8 (12.90)29.6817
2010's30 (48.39)24.3611
2020's1 (1.61)2.80

Authors

AuthorsStudies
Song, YP1
Mistry, H1
Irlam, J1
Valentine, H1
Yang, L1
Lane, B1
West, C1
Choudhury, A2
Hoskin, PJ2
Chen, D1
Eyupoglu, IY1
Savaskan, N1
Martens, S1
Jeong, M1
Tonnus, W1
Feldmann, F1
Hofmans, S1
Goossens, V1
Takahashi, N1
Bräsen, JH1
Lee, EW1
Van der Veken, P1
Joossens, J1
Augustyns, K1
Fulda, S1
Linkermann, A1
Song, J1
Vandenabeele, P1
Paech, F1
Mingard, C1
Grünig, D1
Abegg, VF1
Bouitbir, J1
Krähenbühl, S1
Pajuelo, D1
Gonzalez-Juarbe, N1
Tak, U1
Sun, J1
Orihuela, CJ1
Niederweis, M1
Carlo-Stella, C3
Locatelli, SL3
Giacomini, A2
Cleris, L3
Saba, E2
Righi, M1
Guidetti, A2
Gianni, AM2
Eustace, A1
Irlam, JJ1
Taylor, J1
Denley, H1
Agrawal, S1
Ryder, D1
Ord, JJ1
Harris, AL1
Rojas, AM1
West, CM1
Jakubowicz-Gil, J1
Langner, E1
Bądziul, D1
Wertel, I1
Rzeski, W1
Stirparo, GG1
Tartari, S1
Pierdominici, M1
Malorni, W1
Carbone, A1
Anichini, A2
Fukuda, H1
Numata, K1
Moriya, S1
Shimoyama, Y1
Ishii, T2
Nozaki, A1
Kondo, M1
Morimoto, M1
Maeda, S1
Sakamaki, K1
Morita, S1
Tanaka, K3
Ramírez-Labrada, A1
López-Royuela, N1
Jarauta, V1
Galán-Malo, P1
Azaceta, G1
Palomera, L1
Pardo, J1
Anel, A1
Marzo, I1
Naval, J1
Lachaier, E2
Louandre, C3
Godin, C3
Saidak, Z3
Baert, M1
Diouf, M2
Chauffert, B3
Galmiche, A3
Marcq, I1
Bouhlal, H1
François, C1
Chatelain, D1
Debuysscher, V1
Barbare, JC2
Suzuki, E1
Ooka, Y1
Chiba, T1
Kobayashi, K1
Kanogawa, N1
Motoyama, T1
Saito, T1
Ogasawara, S1
Tawada, A1
Yokosuka, O1
Bodeau, S1
Conte, MA1
Barget, N1
Trinchet, JC1
Ganne, N1
Araki, H1
Tsuzuki, T1
Kimura, T1
Yamada, S1
Sassa, N1
Yoshino, Y1
Hattori, R1
Gotoh, M1
Kharaziha, P1
Chioureas, D1
Baltatzis, G1
Fonseca, P1
Rodriguez, P1
Gogvadze, V1
Lennartsson, L1
Björklund, AC1
Zhivotovsky, B1
Grandér, D1
Egevad, L1
Nilsson, S1
Panaretakis, T1
Kim, GM1
Kim, MD1
Kim, do Y1
Kim, SH1
Won, JY1
Park, SI1
Lee, do Y1
Shin, W1
Shin, M1
Kong, WT1
Cai, H1
Tang, Y1
Zhang, XL1
Wang, WP1
Frederick, DW1
Loro, E1
Liu, L1
Davila, A1
Chellappa, K1
Silverman, IM1
Quinn, WJ1
Gosai, SJ1
Tichy, ED1
Davis, JG1
Mourkioti, F1
Gregory, BD1
Dellinger, RW1
Redpath, P1
Migaud, ME1
Nakamaru-Ogiso, E1
Rabinowitz, JD1
Khurana, TS1
Baur, JA1
Murakami, T1
Igarashi, K1
Kawaguchi, K1
Kiyuna, T1
Zhang, Y1
Zhao, M1
Hiroshima, Y1
Nelson, SD1
Dry, SM1
Li, Y1
Yanagawa, J1
Russell, T1
Federman, N1
Singh, A1
Elliott, I1
Matsuyama, R1
Chishima, T1
Endo, I1
Eilber, FC1
Hoffman, RM1
Tang, Z1
Kang, M1
Zhang, B1
Chen, J1
Fang, H1
Ye, Q1
Jiang, B1
Wu, Y1
Korkmaz, S1
Maupoil, V1
Sobry, C2
Brunet, C1
Chevalier, S2
Freslon, JL1
Horger, M2
Lauer, UM2
Schraml, C1
Berg, CP1
Koppenhöfer, U1
Claussen, CD2
Gregor, M2
Bitzer, M2
Ladoire, S1
Beynat, C1
Diaz, P1
Coudert, B1
Favier, L1
Ghiringhelli, F1
Spira, D1
Fenchel, M1
Mertens, JC1
Martin, IV1
Schmitt, J1
Frei, P1
Bruners, P1
Herweg, C1
Mahnken, AH1
Müllhaupt, B1
Geier, A1
Liu, Q1
Mier, JW1
Panka, DJ1
Petrov, VI1
Ponomarev, ÉA1
Maskin, SS1
Strepetov, NN1
Fabries, P1
Pauleau, G1
Brardjanian, S1
Artéaga, C1
Guisset, M1
Coton, T1
Tong, DL1
Zhang, DX1
Xiang, F1
Teng, M1
Jiang, XP1
Hou, JM1
Zhang, Q1
Huang, YS1
Yang, YY1
Huang, YT1
Lee, TY1
Chan, CC1
Yeh, YC1
Lee, KC1
Lin, HC1
Mortarini, R1
Yang, J1
Klaidman, LK1
Chang, ML1
Kem, S1
Sugawara, T1
Chan, P1
Adams, JD1
Piro, S1
Anello, M1
Di Pietro, C1
Lizzio, MN1
Patanè, G1
Rabuazzo, AM1
Vigneri, R1
Purrello, M1
Purrello, F1
Tronov, VA1
Konstantinov, EM1
Petrakou, E1
Tsilimigaki, S1
Piperakis, SM1
Aikin, R1
Rosenberg, L1
Paraskevas, S1
Maysinger, D1
Hanton, G1
Daguès, N1
Provost, JP1
Le Net, JL1
Comby, P1
Takahashi, S1
Nakae, D1
Yokose, Y1
Emi, Y1
Denda, A1
Mikami, S1
Ohnishi, T1
Konishi, Y1
Elliott, WC1
Houghton, DC1
Gilbert, DN1
Baines-Hunter, J1
Bennett, WM1
Watson, AJ1
Askew, JN1
Benson, RS1
Thomas, CD1
Prade, M1
Guichard, M1
de Ferreyra, EC1
Bernacchi, AS1
San Martín, MF1
Castro, GD1
Castro, JA1
Saldeen, J1
Welsh, N1
Hoorens, A1
Pipeleers, D1
Chatterjee, PK1
Cuzzocrea, S1
Thiemermann, C1
Harel, A1
Bloch, O1
Vardi, P1
Bloch, K1
Schoental, R2
Horita, N1
Oyanagi, S1
Izumiyama, Y1
Szalay, J1
Böti, Z1
Temesvári, P1
Bara, D1
Nakagawa, K1
Miyazaki, M1
Okui, K1
Kato, N1
Moriyama, Y1
Fujimura, S1
Politis, MJ1
Render, JA1
Carlton, WW1
Hinsman, EJ1
Turek, JJ1
Chen, G1
Pan, QC1
Lazarus, SS1
Shapiro, SH1
Severin, SE1
Hill, K1
Neidhardt, M1
Hirsch, GH1
Herken, H1
Keller, K1
Kolbe, H1
Lange, K1
Schneider, H2
Cervos-Navarro, J1
Schweichel, JU1
Merker, HJ1

Trials

2 trials available for niacinamide and Necrosis

ArticleYear
Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
    International journal of radiation oncology, biology, physics, 2021, 08-01, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbon Dioxide; Confidence Intervals; Disease-Fre

2021
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013, Volume: 108, Issue:1

    Topics: Aged; Aged, 80 and over; Carbon Dioxide; Carbonic Anhydrase IV; Cell Hypoxia; Female; Glucose Transp

2013

Other Studies

60 other studies available for niacinamide and Necrosis

ArticleYear
Ferroptosis and Cell Death Analysis by Flow Cytometry.
    Methods in molecular biology (Clifton, N.J.), 2017, Volume: 1601

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dactinomycin; Flow Cytom

2017
Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.
    Cell death & disease, 2017, 06-29, Volume: 8, Issue:6

    Topics: Animals; Apoptosis; Cell Death; Disease Models, Animal; Humans; Inflammation; Mice; Necrosis; Niacin

2017
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
    Toxicology, 2018, 02-15, Volume: 395

    Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans;

2018
NAD
    Cell reports, 2018, 07-10, Volume: 24, Issue:2

    Topics: Animals; Apoptosis; Bacterial Toxins; Biocatalysis; Cytoprotection; Humans; Jurkat Cells; Macrophage

2018
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell

2013
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
    Neurotoxicity research, 2014, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combinatio

2014
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
    Leukemia, 2014, Volume: 28, Issue:9

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carbamates; Cell Line, Tum

2014
Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
    Radiology, 2014, Volume: 272, Issue:2

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Co

2014
Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase Inhibito

2015
Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Humans; L-Lactate Dehydrogenase

2014
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Prolif

2015
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
    Clinical journal of gastroenterology, 2015, Volume: 8, Issue:1

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Hepatic Artery; Humans; In

2015
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
    Anticancer research, 2015, Volume: 35, Issue:3

    Topics: Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Kerat

2015
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
    American journal of clinical pathology, 2015, Volume: 143, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; D

2015
Sorafenib-induced defective autophagy promotes cell death by necroptosis.
    Oncotarget, 2015, Nov-10, Volume: 6, Issue:35

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western

2015
Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
    Journal of vascular and interventional radiology : JVIR, 2016, Volume: 27, Issue:7

    Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepato

2016
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model.
    Discovery medicine, 2016, Volume: 21, Issue:118

    Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magn

2016
Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle.
    Cell metabolism, 2016, 08-09, Volume: 24, Issue:2

    Topics: Administration, Oral; Aging; Animals; Biological Availability; Energy Metabolism; Glucose; Homeostas

2016
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.
    Oncotarget, 2017, Jan-31, Volume: 8, Issue:5

    Topics: Adolescent; Animals; Antineoplastic Agents; Biological Therapy; Bone Neoplasms; Drug Resistance, Neo

2017
Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
    Tumori, 2017, May-12, Volume: 103, Issue:3

    Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease Models, An

2017
An increased regional blood flow precedes mesenteric inflammation in rats treated by a phosphodiesterase 4 inhibitor.
    Toxicological sciences : an official journal of the Society of Toxicology, 2009, Volume: 107, Issue:1

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Analysis of Variance; Animals; A

2009
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
    BMC cancer, 2009, Jun-28, Volume: 9

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Li

2009
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Rena

2010
Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
    Academic radiology, 2011, Volume: 18, Issue:1

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular

2011
Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals.
    European journal of radiology, 2012, Volume: 81, Issue:7

    Topics: Alanine Transaminase; Animals; Benzenesulfonates; Catheter Ablation; Cell Proliferation; Epidermal G

2012
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
    Molecular cancer, 2011, Sep-19, Volume: 10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins;

2011
[Pharmacological neuroprotection against brain damage in ischemiai/reperfusion experiment].
    Eksperimental'naia i klinicheskaia farmakologiia, 2011, Volume: 74, Issue:8

    Topics: Animals; Brain; Drug Combinations; Drug Evaluation, Preclinical; Eosine Yellowish-(YS); Flavin Monon

2011
[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
    Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:2

    Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Agents; Carcinoma, H

2013
Nicotinamide pretreatment protects cardiomyocytes against hypoxia-induced cell death by improving mitochondrial stress.
    Pharmacology, 2012, Volume: 90, Issue:1-2

    Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Apoptosis; Cell Hypoxia; Cells, Cultured; L-Lacta

2012
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012, Volume: 18, Issue:11

    Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; He

2012
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Leukemia, 2013, Volume: 27, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle Proteins; C

2013
Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model.
    Pharmacology, biochemistry, and behavior, 2002, Volume: 73, Issue:4

    Topics: Animals; Apoptosis; Brain; Dose-Response Relationship, Drug; Male; Necrosis; Niacinamide; Rats; Rats

2002
Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress.
    Metabolism: clinical and experimental, 2002, Volume: 51, Issue:10

    Topics: Animals; Annexin A5; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase

2002
Nicotinamide "protects" resting lymphocytes exposed to hydrogen peroxide from necrosis but not from apoptosis.
    Cell biology and toxicology, 2002, Volume: 18, Issue:6

    Topics: Apoptosis; Cell Survival; Comet Assay; DNA Damage; DNA Fragmentation; DNA Repair; Electrophoresis, A

2002
Inhibition of caspase-mediated PARP-1 cleavage results in increased necrosis in isolated islets of Langerhans.
    Journal of molecular medicine (Berlin, Germany), 2004, Volume: 82, Issue:6

    Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase Inhibitors; Caspases; Cell Death; Cells

2004
Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog.
    Toxicology letters, 2008, Jun-10, Volume: 179, Issue:1

    Topics: Acute-Phase Reaction; Administration, Oral; Animals; Azepines; Blood Vessels; C-Reactive Protein; Do

2008
Enhancement of DEN initiation of liver carcinogenesis by inhibitors of NAD+ ADP ribosyl transferase in rats.
    Carcinogenesis, 1984, Volume: 5, Issue:7

    Topics: Animals; Benzamides; Diethylnitrosamine; DNA Repair; gamma-Glutamyltransferase; Liver; Liver Neoplas

1984
Gentamicin nephrotoxicity. I. Degree and permanence of acquired insensitivity.
    The Journal of laboratory and clinical medicine, 1982, Volume: 100, Issue:4

    Topics: Acute Kidney Injury; Animals; Gentamicins; Inulin; Kidney; Kidney Cortex; Male; Necrosis; Niacinamid

1982
Poly(adenosine diphosphate ribose) polymerase inhibition prevents necrosis induced by H2O2 but not apoptosis.
    Gastroenterology, 1995, Volume: 109, Issue:2

    Topics: Aminobenzoates; Apoptosis; Benzamides; Cell Count; Cell Line; DNA Repair; Humans; Hydrogen Peroxide;

1995
Tumour oxygenation, radiosensitivity, and necrosis before and/or after nicotinamide, carbogen and perflubron emulsion administration.
    International journal of radiation biology, 1995, Volume: 67, Issue:5

    Topics: Animals; Carbon Dioxide; Cell Survival; Fluorocarbons; Humans; Hydrocarbons, Brominated; Hypoxia; Mi

1995
Nicotinamide late protective effects against carbon tetrachloride-induced liver necrosis.
    Experimental and molecular pathology, 1994, Volume: 60, Issue:3

    Topics: Animals; Carbon Tetrachloride; Lipid Peroxidation; Liver; Male; Necrosis; Niacinamide; Rats; Rats, S

1994
Nicotinamide-induced apoptosis in insulin producing cells is associated with cleavage of poly(ADP-ribose) polymerase.
    Molecular and cellular endocrinology, 1998, Apr-30, Volume: 139, Issue:1-2

    Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Benzamides; Cell Line; Cysteine Proteinase Inhi

1998
Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis.
    Diabetologia, 1999, Volume: 42, Issue:1

    Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; Cytokines; Humans; Hydrogen Peroxide; Interferon

1999
Inhibitors of poly (ADP-ribose) synthetase protect rat proximal tubular cells against oxidant stress.
    Kidney international, 1999, Volume: 56, Issue:3

    Topics: Animals; Benzamides; Catalase; Cells, Cultured; Deferoxamine; DNA Damage; Enzyme Activation; Enzyme

1999
Sensitivity of HaCat keratinocytes to diabetogenic toxins.
    Biochemical pharmacology, 2002, Jan-15, Volume: 63, Issue:2

    Topics: Alloxan; Analysis of Variance; Apoptosis; Benzamides; Cell Line; Cell Survival; Enzyme Inhibitors; G

2002
Proceedings: Is alkylation of nicotinamide the cause of liver necrosis that follows large doses of hepatocarcinogens?
    British journal of cancer, 1975, Volume: 32, Issue:2

    Topics: Carcinogens; Chemical and Drug Induced Liver Injury; Liver; Necrosis; Niacinamide

1975
Ultrastructure of 6-aminonicotinamide (6-an)--induced lesions in the central nervous system of rats.
    Acta neuropathologica, 1978, Nov-15, Volume: 44, Issue:2

    Topics: 6-Aminonicotinamide; Animals; Anterior Horn Cells; Axons; Male; Microscopy, Electron; Necrosis; Neur

1978
Alterations of the nucleus ruber in 3-acetylpyridine intoxication. A light and electron microscopic study.
    Experimentelle Pathologie, 1979, Volume: 17, Issue:5

    Topics: Animals; Antimetabolites; Female; Male; Microscopy, Electron; Mitochondria; Necrosis; Niacinamide; O

1979
Biochemical basis of liver necrosis caused by pyrrolizidine alkaloids and certain other hepatotoxins.
    Biochemical Society transactions, 1975, Volume: 3, Issue:2

    Topics: Alkylation; Animals; Chemical and Drug Induced Liver Injury; NAD; Necrosis; Niacinamide; Pyridones;

1975
N1-methylnicotinamide level in the blood after nicotinamide loading as further evidence for malignant tumor burden.
    Japanese journal of cancer research : Gann, 1991, Volume: 82, Issue:11

    Topics: Animals; Carbon Tetrachloride Poisoning; Cells, Cultured; DNA Replication; Galactosamine; Inflammati

1991
6-Aminonicotinamide selectively causes necrosis in reactive astroglia cells in vivo. Preliminary morphological observations.
    Journal of the neurological sciences, 1989, Volume: 92, Issue:1

    Topics: 6-Aminonicotinamide; Animals; Astrocytes; Cell Nucleus; Male; Necrosis; Nerve Degeneration; Niacinam

1989
Pathology of 6-aminonicotinamide toxicosis in the rabbit.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 1985, Volume: 23, Issue:9

    Topics: 6-Aminonicotinamide; Animals; Female; Injections, Intraperitoneal; Male; Microscopy, Electron; Necro

1985
Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide.
    Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Ehrlich Tumor; Cispl

1988
Influence of nicotinamide and pyridine nucleotides on streptozotocin and alloxan-induced pancreatic B cell cytotoxicity.
    Diabetes, 1973, Volume: 22, Issue:7

    Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Islets of Langerhans; Male; Mice; NAD;

1973
[Basic directions in the study of the biochemistry of the myocardium].
    Kardiologiia, 1967, Volume: 7, Issue:11

    Topics: Adaptation, Physiological; Animals; Camphor; Cardiac Glycosides; Cardiomegaly; Cardiovascular Diseas

1967
[Familial, infantile-septic chronic granulomatous disease: pathology and pathogenesis].
    Deutsche medizinische Wochenschrift (1946), 1970, Aug-14, Volume: 95, Issue:33

    Topics: Child, Preschool; Granuloma; Histiocytes; Humans; Leukocytes; Male; Necrosis; Niacinamide; Oxidoredu

1970
Stimulation of renal organic base transport by uranyl nitrate.
    Canadian journal of physiology and pharmacology, 1972, Volume: 50, Issue:6

    Topics: Aminohippuric Acids; Animals; Biological Transport; Body Weight; Carbon Isotopes; Kidney; Kinetics;

1972
[Experimental myelopathy--biochemical basis of its cellular pathogenesis (author's transl)].
    Klinische Wochenschrift, 1973, Jul-01, Volume: 51, Issue:3

    Topics: Animals; Brain Chemistry; Disease Models, Animal; Endoplasmic Reticulum; Gluconates; Glycoside Hydro

1973
Acute gliopathy in spinal cord and brain stem induced by 6-aminonicotinamide.
    Acta neuropathologica, 1974, Feb-07, Volume: 27, Issue:1

    Topics: Animals; Brain Stem; Cats; Cell Nucleus; Cerebellum; Cranial Nerves; Cytoplasm; Endoplasmic Reticulu

1974
The morphology of various types of cell death in prenatal tissues.
    Teratology, 1973, Volume: 7, Issue:3

    Topics: Abnormalities, Drug-Induced; Animals; Cell Survival; Cyclophosphamide; Dactinomycin; Embryo, Mammali

1973